Replies to post #223489 on Biotech Values

[DewDiligence]

ABBV/(ENTA) had a 54%* worldwide share of 4Q18 combined ABBV/GILD HCV sales (#msg-146335275, #msg-146568699).

*$862M/$1,600M.

[DewDiligence]

GILD 4Q18 CC slides:

http://investors.gilead.com/static-files/d37c8017-5ae2-40d1-b8e3-371604c33341

[DewDiligence]

GILD 1Q19 HCV sales=$790M, +7% QoQ:

http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-announces-first-quarter-2019-financial-results

GILD’s 1Q19 US HCV sales were $393M, -6% QoQ; GILD’s 1Q19 ex-US HCV sales were $397M, +25% QoQ.